scholarly journals Interactions between antidepressants, sleep aids and selected breast cancer therapy

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Jody Jacobson Wedret ◽  
Thanh G. Tu ◽  
Doru Paul ◽  
Camille Rousseau ◽  
Augustin Bonta ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Survival Rates ◽  
Chemical Properties ◽  
Drug Level ◽  
Disease States ◽  
Estrogen Receptor Modulators ◽  
Tamoxifen Metabolism ◽  
Potential Impact ◽  
Receptor Modulators

Depression and insomnia are very significant pathologies in cancer patients as they contribute to the patient’s overall cure and quality of life. Moreover, untreated depression and ongoing insomnia are associated with decreased immune responses and lower survival rates. With all disease states and especially with cancer, close attention to drug-drug interactions and the potential impact on the efficacy of therapy is paramount. One area of particular interest due to the lack of well-done clinical trials is drug-drug interaction(s) between antidepressants and cancer treatment. Pharmacokinetics of a certain drug allows for prediction of certain drug interactions based on chemical properties of the agents involved. If the agents depend on their metabolites for activity, active drug level will be decreased through this enzyme inhibition. In this paper, we looked at the cytochrome-P450 drug interactions between antidepressants and sleep aids with Selective Estrogen Receptor Modulators (SERM). Newer SERM metabolisms are less influenced by interactions with medications used to treat depression. However, tamoxifen metabolism could be severely altered by several antidepressants. This has direct consequences as patients on tamoxifen and antidepressant can have double the risk of relapse to cancer in two years. We discussed those interactions and made recommendations for clinical use.

scholarly journals Interactions between antidepressants, sleep aids and selected breast cancer therapy

2019 ◽  
Vol 11 (1) ◽  
pp. 36-38
Author(s):  
Jody Jacobson Wedret ◽  
Thanh G. Tu ◽  
Doru Paul ◽  
Camille Rousseau ◽  
Augustin Bonta ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Survival Rates ◽  
Chemical Properties ◽  
Drug Level ◽  
Disease States ◽  
Estrogen Receptor Modulators ◽  
Tamoxifen Metabolism ◽  
Potential Impact ◽  
Receptor Modulators

Depression and insomnia are very significant pathologies in cancer patients as they contribute to the patient's overall cure and quality of life. Moreover, untreated depression and ongoing insomnia are associated with decreased immune responses and lower survival rates. With all disease states and especially with cancer, close attention to drug-drug interactions and the potential impact on the efficacy of therapy is paramount. One area of particular interest due to the lack of well-done clinical trials is drug-drug interaction(s) between antidepressants and cancer treatment. Pharmacokinetics of a certain drug allows for prediction of certain drug interactions based on chemical properties of the agents involved. If the agents depend on their metabolites for activity, active drug level will be decreased through this enzyme inhibition. In this paper, we looked at the cytochrome-P450 drug interactions between antidepressants and sleep aids with Selective Estrogen Receptor Modulators (SERM). Newer SERM metabolisms are less influenced by interactions with medications used to treat depression. However, tamoxifen metabolism could be severely altered by several antidepressants. This has direct consequences as patients on tamoxifen and antidepressant can have double the risk of relapse to cancer in two years. We discussed those interactions and made recommendations for clinical use.

scholarly journals NEW APPROACHES TO OSTEOPOROSIS IN PRIMARY CARE

2017 ◽  
Vol 12 (4) ◽  
pp. 184-191
Author(s):  
Mihaela Daniela BALTĂ ◽  
◽  
Mihaela Adela IANCU ◽  
Dumitru MATEI ◽  
◽  
...  
Keyword(s):  
Hormone Replacement ◽  
Adherence To Treatment ◽  
Treatment Of Osteoporosis ◽  
Estrogen Receptor Modulators ◽  
Aging Populations ◽  
Receptor Modulators ◽  
Current Guidelines ◽  
Frax Score ◽  
Insight Into

Osteoporosis is a disease that affects an increasing number of people, given the tendency of aging populations. Fragile bone and increases risk of bones breaking, their consequences, impairment of quality of life have prompted health policies to provide a greater insight into this condition. It is important to identify the risk factors and start the preventive and curative treatment as early as possible. Current guidelines recommend using the FRAX score to determine the risk of major fracture over the next 10 years, followed by DXA determination. The current guidelines highlight the importance of non-medication measures, calcium and vitamin D intake. Among the therapeutic agents used in the treatment of osteoporosis, the first line are bisphosphonates poor, in case of intolerance, bisphosphonates iv or antibodies anti RANKL (denosumab). Selective estrogen receptor modulators and hormone replacement therapy are not routinely indicated, and recombinant PTH is expensive and is intended for severe and resistant forms. The adherence to treatment is poor, so we need measures to increase prevention, screening and early treatment of osteoporosis, as well as measures to educate the population.

scholarly journals Menopausal hormone therapy: Benefits and different forms

2016 ◽  
Vol 69 (7-8) ◽  
pp. 247-254 ◽  
Author(s):  
Ranko Kutlesic ◽  
Jasmina Popovic ◽  
Milan Stefanovic ◽  
Predrag Vukomanovic ◽  
Aleksandra Andric ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Symptom Control ◽  
Menopausal Hormone Therapy ◽  
Actual Condition ◽  
Ovarian Hormone ◽  
Hormone Production ◽  
Estrogen Receptor Modulators ◽  
Potential Risks ◽  
Receptor Modulators

Introduction. Declining of ovarian hormone production can seriously disturb the quality of woman?s life, with physical and emotional consequences and to potentiate the development of additional health risks such as cardiovascular diseases and osteoporosis which are already present in women of older age. Benefits of Menopausal Hormone Therapy. Menopausal hormone therapy ameliorates the quality of life by resolving the atrophic symptoms and vasomotor problems, protecting from the osteoporosis, maintaining the skin and connective tissue turgor, as well as by improving libido, mood and depression during the menopausal transition. Forms of Menopausal Hormone Therapy. There are several possibilities to treat menopausal problems: estrogen, combination of estrogen and progestogen, androgens, selective estrogen receptor modulators, tissue selective estrogen complex, tibolon and alternatives. Initiating, Monitoring and Discontinuing Menopausal Hormone Therapy. Menopausal hormone therapy should be started when the problems due to menopausal symptoms appear. It is important to have on mind that the effects of hormones depend on age and actual condition of the woman?s organism. The goal is effective treatment at the lowest dose and during the shortest interval needed for symptom control. The therapy must be reevaluated every year and potential risks must be discussed as well. Conclusion. Menopausal hormone therapy ameliorates the quality of woman?s life in perimenopause. Type, doses and duration of the menopausal hormone therapy should be individualized.

Superselective Radioembolization of Hepatocellular Carcinoma: 5-Year Results of a Prospective Study

1994 ◽  
Vol 33 (05) ◽  
pp. 206-214 ◽  
Author(s):  
J. Triller ◽  
H. U. Baer ◽  
Livia Geiger ◽  
H. F. Beer ◽  
C. Becker ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Rates ◽  
Absorbed Dose ◽  
Pulmonary Complications ◽  
Pulmonary Shunt ◽  
Recurrent Tumour ◽  
Activity Distribution ◽  
A Prospective Study ◽  
Overall Survival Rates

SummaryTwenty patients with unresectable hepatocellular carcinoma (HCC) were followed up to 5 years after transarterial radiotherapy with 90Y-resin particles. Diagnostic radioembolizations of 99mTc-macroaggregates facilitated scintigraphic assessment of activity distribution, dose evaluation and final procedural verification. The overall survival rates were 56, 38 and 14% (after 1, 2 and 3 years, resp.). Patients with unifocal HCC and a single feeding artery (n = 7) even presented 83, 67 and 40% (2 alive after 2.75 and 4 years). With multiple arteries (n = 7), the longest survival was 26 months. Patients with multifocal HCC survived up to 33 months after selective radioembolization. Quality of life was improved in all. Survival was positively correlated with absorbed dose but residual/recurrent tumour occurred even after ≥300 Gy. Post-treatment symptoms were minimal (35 applications), pulmonary shunt rates were correctly predicted and pulmonary complications avoided.

’Propylene glycolate’ used as a top coat seal to protect thick juice from degradation in ellipsoidal storage tanks

2013 ◽  
pp. 215-218
Author(s):  
Robert O. Hatch ◽  
Craig M. Giles ◽  
Jay S. Creiglow ◽  
David R. Smith
Keyword(s):  
Propylene Glycol ◽  
Barrier Layer ◽  
Chemical Properties ◽  
Polypropylene Glycol ◽  
Storage Tanks ◽  
First Results ◽  
Thick Juice

The use of sodium propylene glycol for thick juice storage was investigated at Spreckels Sugar Company, in Brawley, California (USA). Sodium-polypropylene glycol has a density of 1.07 and does not mix with thick juice. Therefore it is suitable as a barrier layer. Chemical properties of propylene glycol, and the deposition on the top of thick juice are described. First results of the last campaign are compared with data from previous years. A significantly lower tendency in the reduction of the quality of the thick juice was found.

Sign in / Sign up

Export Citation Format

Share Document